Fat Loss & GH Stack

One of these peptides did something almost none of its peers ever will: it earned FDA approval. Tesamorelin went through full clinical development as Egrifta®, with randomized controlled trials demonstrating roughly 15–18% reductions in visceral abdominal fat over 6–12 months — without perturbing glucose metabolism [PMID: 20101189] [PMID: 25038357]. A subsequent JAMA-published replication extended the record to hepatic fat [PMID: 25038357]. The Fat Loss & GH Stack pairs that proven GHRH analog with Ipamorelin, a selective ghrelin-receptor agonist described in the literature as having GH-release selectivity comparable to GHRH itself [PMID: 9849822].

The scientific logic follows the GH axis itself. Pituitary somatotroph cells integrate two independent signals — GHRH driving GH gene transcription and synthesis via cAMP, ghrelin amplifying each pulse's amplitude by modulating somatostatin tone — and preclinical evidence suggests firing both together yields synergistic release significantly exceeding either signal alone [PMID: 11549707]. For anyone researching visceral fat that resists diet and training no matter what, this is the pairing where clinical-grade evidence meets mechanistic synergy.

Below you'll find the two-signal physiology, the trial record in human terms, and the honest asymmetry between these compounds' evidence bases. Tesamorelin's approval covers one narrow indication (HIV-associated lipodystrophy); ipamorelin remains investigational with no approved therapeutic use — and no trial has tested the combination itself.

Growth hormone secretion is a two-input system, and the physiology deserves telling properly. GHRH binds its receptor on pituitary somatotrophs, raising intracellular cAMP and driving GH gene transcription and hormone release. Ghrelin arrives through GHSR-1a via a separate phospholipase C/IP₃/calcium pathway that amplifies each pulse — partly by loosening somatostatin's brake [PMID: 16906274]. Endogenous ghrelin reads less like a trigger and more like the amplifier riding the volume knob of the basic pulsatile pattern, optimizing somatotroph responsiveness to GHRH around the clock [PMID: 16906274].

Tesamorelin supplies the first input with unusual credentials. The synthetic GHRH analog (the 44-amino-acid human sequence plus a trans-3-hexenoyl group at the N-terminus) powered a landmark 12-month randomized trial of 404 participants: approximately 18% less visceral adipose tissue versus placebo (P < 0.0001), significant improvements in trunk fat, waist circumference, and waist-hip ratio — and, critically for anyone tracking metabolic variables, no significant change in fasting glucose [PMID: 20101189]. A JAMA-published RCT replicated the visceral findings and added hepatic fat reduction (−2.0% versus +0.9% on placebo, P = .003) [PMID: 25038357]. Secondary analyses found responders gained skeletal muscle area and density, hinting at favorable body-composition shifts beyond fat reduction alone [PMID: 31237318]. The hepatic-fat signal held across independent trials, strengthening the visceral findings considerably [PMID: 25038357].

Ipamorelin supplies the second input with its own distinction. Engel et al. demonstrated GH release from rat pituitary cells comparable to GHRP-6 in potency and efficacy (EC₅₀ = 1.3 nmol/L) — without ACTH or cortisol elevation even at doses more than 200-fold beyond its effective dose [PMID: 9849822]. Every earlier GHRP failed that test, which is why their cortisol spillover complicated research interpretations. Pharmacokinetic modeling adds a pulsatile-friendly profile: a single GH episode peaking near 0.67 hours, then declining exponentially [PMID: 10496658].

Combine the two and you mirror the axis's native wiring. Hataya et al. showed that GHRH plus ghrelin at sub-threshold doses produced synergistic GH release — significantly greater than either peptide's additive effect [PMID: 11549707]. Mapping that synergy onto tesamorelin and ipamorelin is elegant, and entirely extrapolated: no trial has ever tested the pairing in humans. That gap defines the current research frontier.

A defining convenience: both peptides go under the skin, which simplifies combined protocol design compared to stacks mixing routes. What differs sharply is evidence depth. Tesamorelin carries a fixed studied dose — 2 mg/day subcutaneous, established through its clinical development program across randomized controlled trials spanning up to 52 weeks [PMID: 20101189] [PMID: 25038357]. Ipamorelin's dosing ranges from low nanomole-per-kilogram concentrations in animal models [PMID: 9849822] to various infusion doses explored in phase 2 human studies for postoperative ileus [PMID: 25331030]. Human experience with the fragment remains confined to those surgical contexts [PMID: 25331030].

That asymmetry matters for anyone designing combined protocols and must shape how results are interpreted. One compound brings a well-characterized human safety and efficacy profile from controlled trials; the other offers limited surgical-context studies with no long-term body-composition record in humans. Accounting for uneven evidence isn't optional — it determines what any combined experiment can honestly claim to show.

Half-lives push both toward consistent daily scheduling. Tesamorelin's elimination half-life runs approximately 26–38 minutes; ipamorelin's GH-stimulating effect peaks around 0.67 hours and decays exponentially [PMID: 10496658]. One approach described in the research context keeps the established tesamorelin schedule [PMID: 20101189] while adding ipamorelin informed by the ghrelin-agonist literature; anecdotal protocol spans run 8 to 16 weeks, matching tesamorelin's clinical observation windows.

No standardized combined protocol exists; everything available reflects single-compound clinical data or preclinical extrapolation from synergy studies. The questions readers bring to that gap come next.